The chassis microorganisms are used to carry out genetic engineering editing, editing and regulation of metabolic pathways, and efficient biosynthesis technology for the production of the main substances in HMOs (2'-FL, 3-FL, LNT, LNnT) is realized through strain screening, strain fermentation, purification, detection and other processes.

The company uses biotechnology + AI to drive synthetic biology intelligent manufacturing, and takes the lead in realizing the pilot scale-up of lactose N tetraose (LNT) and lactose N neotetraose (LNnT) in HMOs in China, and the product quality has reached the industry-leading standard.

Advanced microbial technology is used to screen and cultivate efficient methanogenic strains for the treatment of biomass waste liquid, and at the same time provide suitable temperature, sufficient nutrients and strict anaerobic environment for methanogens, so as to achieve stable methane output.

Through the combined anaerobic fermentation of a variety of biomass wastes, the process can increase the treatment capacity of kitchen waste by about 30% and increase the output of methane by more than 25%, which is the first in China and has reached the industry-leading level.

The reaction process is continuously catalyzed by biological enzymes, and the waste oil is converted into biodiesel at room temperature and pressure at 37°C, and without the use of acid-base catalysts.

Luculent is the first enterprise in China to use the biological enzymatic method to produce waste oil into biodiesel on a large scale, and Luculent Guangzhou biodiesel project has been selected into the public list of the first batch of refueling pilot projects by the National Energy Administration on April 2, 2024.